| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 |
| | 10-K | 10-K | 10-K |
| Revenues: |
| Patient services | 166.8 | 124.1 | 116.8 |
| Clinical trials & other | 6.4 | 6.4 | 6.8 |
| Dispensary | 79.3 | 72.6 | 63.9 |
| FFS revenue | 105.4 | 69.8 | |
| Total revenues | 252.5 | 203.0 | 187.5 |
| Revenue growth [+] | 24.4% | 8.3% | |
| Patient services | 34.4% | 6.2% | |
| Clinical trials & other | -0.4% | -6.3% | |
| Dispensary | 9.4% | 13.6% | |
| FFS revenue | 51.1% | | |
| Dispensary revenue | 9.4% | | |
| Cost of goods sold | 200.4 | 33.1 | 150.6 |
| Gross profit | 52.1 | 169.9 | 36.9 |
| Gross margin | 20.6% | 83.7% | 19.7% |
| Selling, general and administrative | 119.7 | 83.4 | 41.9 |
| Other operating expenses | | 129.0 | |
| EBITDA [+] | -67.6 | -42.5 | -5.0 |
| EBITDA growth | 59.0% | 747.1% | |
| EBITDA margin | -26.8% | -20.9% | -2.7% |
| Depreciation | 1.5 | 0.8 | 0.7 |
| EBITA | -69.1 | -43.3 | -5.7 |
| EBITA margin | -27.4% | -21.4% | -3.0% |
| Amortization of intangibles | 2.9 | 2.5 | 2.5 |
| EBIT [+] | -72.0 | -45.9 | -8.2 |
| EBIT growth | 57.0% | 459.4% | |
| EBIT margin | -28.5% | -22.6% | -4.4% |
| Non-recurring items [+] | 9.9 | | |
| Asset impairment | 9.9 | | |
| Interest expense | 4.1 | 0.3 | 0.3 |
| Interest expense | 4.1 | 0.3 | 0.3 |
| Other income (expense), net [+] | 85.9 | 34.6 | -6.3 |
| Gain (loss) on debt retirement | 0.2 | 5.0 | |
| Gain (loss) on derivative instruments | -24.2 | | |
| Change in fair value of warrants | -1.8 | -3.7 | |
| Change in value of contingent liability | -59.2 | -24.9 | |
| Other | 0.5 | 1.0 | -6.3 |
| Pre-tax income | -0.1 | -11.6 | -14.8 |
| Income taxes | -0.2 | -0.7 | -0.5 |
| Tax rate | 267.0% | 5.8% | 3.3% |
| Net income | -17.0 | -10.6 | -14.3 |
| Net margin | -6.7% | -5.2% | -7.6% |
| |
| Basic EPS [+] | ($0.23) | ($0.16) | ($0.24) |
| Growth | 45.4% | -33.8% | |
| Diluted EPS [+] | ($0.21) | ($0.16) | ($0.24) |
| Growth | 31.3% | -33.8% | |
| |
| Shares outstanding (basic) [+] | 72.8 | 66.2 | 59.1 |
| Growth | 9.9% | 12.0% | |
| Shares outstanding (diluted) [+] | 80.6 | 66.2 | 59.1 |
| Growth | 21.7% | 12.0% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |